Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Alimentation Couche Tard Inc. Stock Falls Wednesday, Underperforms Market

Alimentation Couche Tard Inc. Stock Falls Wednesday, Underperforms Market

Dow JonesDow Jones2026/08/12 20:31

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Alimentation Couche Tard Inc. ATD slid 0.88% to C$92.37 Wednesday, in what proved to be an otherwise all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.51% to 36,662.14.

Alimentation Couche Tard Inc. closed 2.9% below its 52-week high of C$95.15, which the company reached on June 24th.

Trading volume of 1.1 M shares remained below its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 12, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

August 12, 2026 16:31 ET (20:31 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas